nodes	percent_of_prediction	percent_of_DWPC	metapath
Cyproterone acetate—AR—Coregulation of Androgen receptor activity—NCOA4—thyroid cancer	0.0147	0.0554	CbGpPWpGaD
Cyproterone acetate—AR—Regulation of Androgen receptor activity—TRIM24—thyroid cancer	0.0124	0.047	CbGpPWpGaD
Cyproterone acetate—AR—Androgen receptor signaling pathway—NCOA4—thyroid cancer	0.0108	0.0409	CbGpPWpGaD
Cyproterone acetate—AR—Nuclear Receptors—THRB—thyroid cancer	0.0105	0.0395	CbGpPWpGaD
Cyproterone acetate—AR—Regulation of nuclear SMAD2/3 signaling—CITED1—thyroid cancer	0.0104	0.0394	CbGpPWpGaD
Cyproterone acetate—NR3C1—Regulation of Androgen receptor activity—TRIM24—thyroid cancer	0.00944	0.0356	CbGpPWpGaD
Cyproterone acetate—AR—Nuclear Receptor transcription pathway—THRB—thyroid cancer	0.00827	0.0312	CbGpPWpGaD
Cyproterone acetate—NR3C1—Nuclear Receptors—THRB—thyroid cancer	0.00794	0.03	CbGpPWpGaD
Cyproterone acetate—NR3C1—Regulation of nuclear SMAD2/3 signaling—CITED1—thyroid cancer	0.00791	0.0299	CbGpPWpGaD
Cyproterone acetate—NR3C1—FOXA2 and FOXA3 transcription factor networks—NKX2-1—thyroid cancer	0.0074	0.0279	CbGpPWpGaD
Cyproterone acetate—NR3C1—Nuclear Receptor transcription pathway—THRB—thyroid cancer	0.00627	0.0237	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Endogenous sterols—RXRA—thyroid cancer	0.00572	0.0216	CbGpPWpGaD
Cyproterone acetate—AR—Regulation of nuclear beta catenin signaling and target gene transcription—TCF7L1—thyroid cancer	0.00532	0.0201	CbGpPWpGaD
Cyproterone acetate—NR3C1—Endoderm Differentiation—NKX2-1—thyroid cancer	0.00522	0.0197	CbGpPWpGaD
Cyproterone acetate—NR3C1—Transcription factor regulation in adipogenesis—RXRA—thyroid cancer	0.00522	0.0197	CbGpPWpGaD
Cyproterone acetate—AR—Nuclear Receptors—RXRA—thyroid cancer	0.00445	0.0168	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metapathway biotransformation—CHST14—thyroid cancer	0.00387	0.0146	CbGpPWpGaD
Cyproterone acetate—AR—SIDS Susceptibility Pathways—RET—thyroid cancer	0.00364	0.0137	CbGpPWpGaD
Cyproterone acetate—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—BRAF—thyroid cancer	0.00361	0.0136	CbGpPWpGaD
Cyproterone acetate—AR—Nuclear Receptor transcription pathway—RXRA—thyroid cancer	0.00351	0.0133	CbGpPWpGaD
Cyproterone acetate—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—RXRA—thyroid cancer	0.00345	0.013	CbGpPWpGaD
Cyproterone acetate—AR—Regulation of Androgen receptor activity—RXRA—thyroid cancer	0.00341	0.0129	CbGpPWpGaD
Cyproterone acetate—AR—SIDS Susceptibility Pathways—THRB—thyroid cancer	0.00338	0.0128	CbGpPWpGaD
Cyproterone acetate—NR3C1—Nuclear Receptors—RXRA—thyroid cancer	0.00337	0.0127	CbGpPWpGaD
Cyproterone acetate—NR3C1—Transcription factor regulation in adipogenesis—PPARG—thyroid cancer	0.0033	0.0124	CbGpPWpGaD
Cyproterone acetate—AR—Nuclear Receptors—PPARG—thyroid cancer	0.00281	0.0106	CbGpPWpGaD
Cyproterone acetate—AR—Notch-mediated HES/HEY network—HIF1A—thyroid cancer	0.00279	0.0105	CbGpPWpGaD
Cyproterone acetate—NR3C1—SIDS Susceptibility Pathways—RET—thyroid cancer	0.00276	0.0104	CbGpPWpGaD
Cyproterone acetate—NR3C1—Nuclear Receptor transcription pathway—RXRA—thyroid cancer	0.00267	0.0101	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.00265	0.01	CbGpPWpGaD
Cyproterone acetate—NR3C1—Regulation of Androgen receptor activity—RXRA—thyroid cancer	0.00258	0.00976	CbGpPWpGaD
Cyproterone acetate—NR3C1—SIDS Susceptibility Pathways—THRB—thyroid cancer	0.00257	0.00968	CbGpPWpGaD
Cyproterone acetate—NR3C1—Circadian Clock—RXRA—thyroid cancer	0.00251	0.00947	CbGpPWpGaD
Cyproterone acetate—AR—Integrated Breast Cancer Pathway—TPR—thyroid cancer	0.00234	0.00885	CbGpPWpGaD
Cyproterone acetate—AR—SIDS Susceptibility Pathways—PRKAR1A—thyroid cancer	0.00225	0.00848	CbGpPWpGaD
Cyproterone acetate—NR3C1—AP-1 transcription factor network—CDK1—thyroid cancer	0.00223	0.00842	CbGpPWpGaD
Cyproterone acetate—AR—Nuclear Receptor transcription pathway—PPARG—thyroid cancer	0.00222	0.00837	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.00215	0.00812	CbGpPWpGaD
Cyproterone acetate—NR3C1—Nuclear Receptors—PPARG—thyroid cancer	0.00213	0.00804	CbGpPWpGaD
Cyproterone acetate—Mediastinal disorder—Sorafenib—thyroid cancer	0.00211	0.00287	CcSEcCtD
Cyproterone acetate—Constipation—Vandetanib—thyroid cancer	0.00211	0.00287	CcSEcCtD
Cyproterone acetate—Alopecia—Sorafenib—thyroid cancer	0.00207	0.00282	CcSEcCtD
Cyproterone acetate—Mental disorder—Sorafenib—thyroid cancer	0.00205	0.00279	CcSEcCtD
Cyproterone acetate—Malnutrition—Sorafenib—thyroid cancer	0.00204	0.00278	CcSEcCtD
Cyproterone acetate—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00202	0.00275	CcSEcCtD
Cyproterone acetate—CYP19A1—Integrated Breast Cancer Pathway—TPR—thyroid cancer	0.00202	0.00762	CbGpPWpGaD
Cyproterone acetate—Breast pain—Epirubicin—thyroid cancer	0.00198	0.00269	CcSEcCtD
Cyproterone acetate—AR—Generic Transcription Pathway—TRIM33—thyroid cancer	0.00198	0.00746	CbGpPWpGaD
Cyproterone acetate—Cardiovascular disorder—Epirubicin—thyroid cancer	0.00196	0.00267	CcSEcCtD
Cyproterone acetate—Jaundice cholestatic—Epirubicin—thyroid cancer	0.00196	0.00267	CcSEcCtD
Cyproterone acetate—Body temperature increased—Vandetanib—thyroid cancer	0.00195	0.00265	CcSEcCtD
Cyproterone acetate—Abdominal pain—Vandetanib—thyroid cancer	0.00195	0.00265	CcSEcCtD
Cyproterone acetate—Skin discolouration—Epirubicin—thyroid cancer	0.00191	0.0026	CcSEcCtD
Cyproterone acetate—AR—Regulation of nuclear beta catenin signaling and target gene transcription—TERT—thyroid cancer	0.0019	0.00718	CbGpPWpGaD
Cyproterone acetate—Anaemia—Sorafenib—thyroid cancer	0.00189	0.00257	CcSEcCtD
Cyproterone acetate—Cough increased—Epirubicin—thyroid cancer	0.00188	0.00256	CcSEcCtD
Cyproterone acetate—Glossitis—Epirubicin—thyroid cancer	0.00187	0.00255	CcSEcCtD
Cyproterone acetate—NR3C1—Circadian Clock—HIF1A—thyroid cancer	0.00186	0.00703	CbGpPWpGaD
Cyproterone acetate—Syncope—Sorafenib—thyroid cancer	0.00183	0.00249	CcSEcCtD
Cyproterone acetate—Breast pain—Doxorubicin—thyroid cancer	0.00183	0.00249	CcSEcCtD
Cyproterone acetate—Leukopenia—Sorafenib—thyroid cancer	0.00183	0.00248	CcSEcCtD
Cyproterone acetate—Jaundice cholestatic—Doxorubicin—thyroid cancer	0.00182	0.00247	CcSEcCtD
Cyproterone acetate—Cardiovascular disorder—Doxorubicin—thyroid cancer	0.00182	0.00247	CcSEcCtD
Cyproterone acetate—Creatinine increased—Epirubicin—thyroid cancer	0.00181	0.00247	CcSEcCtD
Cyproterone acetate—Loss of consciousness—Sorafenib—thyroid cancer	0.00179	0.00244	CcSEcCtD
Cyproterone acetate—Cough—Sorafenib—thyroid cancer	0.00178	0.00242	CcSEcCtD
Cyproterone acetate—AR—SIDS Susceptibility Pathways—SST—thyroid cancer	0.00178	0.00671	CbGpPWpGaD
Cyproterone acetate—Asthenia—Vandetanib—thyroid cancer	0.00177	0.00241	CcSEcCtD
Cyproterone acetate—Gait disturbance—Epirubicin—thyroid cancer	0.00177	0.0024	CcSEcCtD
Cyproterone acetate—Skin discolouration—Doxorubicin—thyroid cancer	0.00177	0.0024	CcSEcCtD
Cyproterone acetate—Pruritus—Vandetanib—thyroid cancer	0.00175	0.00238	CcSEcCtD
Cyproterone acetate—Cough increased—Doxorubicin—thyroid cancer	0.00174	0.00237	CcSEcCtD
Cyproterone acetate—Glossitis—Doxorubicin—thyroid cancer	0.00173	0.00236	CcSEcCtD
Cyproterone acetate—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.00173	0.00235	CcSEcCtD
Cyproterone acetate—Pulmonary embolism—Epirubicin—thyroid cancer	0.00173	0.00235	CcSEcCtD
Cyproterone acetate—Injection site reaction—Epirubicin—thyroid cancer	0.00172	0.00233	CcSEcCtD
Cyproterone acetate—NR3C1—SIDS Susceptibility Pathways—PRKAR1A—thyroid cancer	0.0017	0.00644	CbGpPWpGaD
Cyproterone acetate—Diarrhoea—Vandetanib—thyroid cancer	0.00169	0.0023	CcSEcCtD
Cyproterone acetate—NR3C1—Nuclear Receptor transcription pathway—PPARG—thyroid cancer	0.00168	0.00635	CbGpPWpGaD
Cyproterone acetate—Creatinine increased—Doxorubicin—thyroid cancer	0.00168	0.00228	CcSEcCtD
Cyproterone acetate—Shock—Sorafenib—thyroid cancer	0.00164	0.00223	CcSEcCtD
Cyproterone acetate—Fluid retention—Epirubicin—thyroid cancer	0.00164	0.00223	CcSEcCtD
Cyproterone acetate—Gait disturbance—Doxorubicin—thyroid cancer	0.00164	0.00222	CcSEcCtD
Cyproterone acetate—Nervous system disorder—Sorafenib—thyroid cancer	0.00163	0.00222	CcSEcCtD
Cyproterone acetate—Dizziness—Vandetanib—thyroid cancer	0.00163	0.00222	CcSEcCtD
Cyproterone acetate—Thrombocytopenia—Sorafenib—thyroid cancer	0.00163	0.00222	CcSEcCtD
Cyproterone acetate—Skin disorder—Sorafenib—thyroid cancer	0.00162	0.0022	CcSEcCtD
Cyproterone acetate—Pulmonary embolism—Doxorubicin—thyroid cancer	0.0016	0.00217	CcSEcCtD
Cyproterone acetate—Anorexia—Sorafenib—thyroid cancer	0.00159	0.00216	CcSEcCtD
Cyproterone acetate—Injection site reaction—Doxorubicin—thyroid cancer	0.00159	0.00216	CcSEcCtD
Cyproterone acetate—Coma—Epirubicin—thyroid cancer	0.00158	0.00214	CcSEcCtD
Cyproterone acetate—Vomiting—Vandetanib—thyroid cancer	0.00157	0.00214	CcSEcCtD
Cyproterone acetate—Rash maculo-papular—Epirubicin—thyroid cancer	0.00157	0.00213	CcSEcCtD
Cyproterone acetate—Neoplasm—Epirubicin—thyroid cancer	0.00156	0.00212	CcSEcCtD
Cyproterone acetate—Rash—Vandetanib—thyroid cancer	0.00156	0.00212	CcSEcCtD
Cyproterone acetate—Dermatitis—Vandetanib—thyroid cancer	0.00156	0.00212	CcSEcCtD
Cyproterone acetate—Headache—Vandetanib—thyroid cancer	0.00155	0.0021	CcSEcCtD
Cyproterone acetate—NR3C1—AP-1 transcription factor network—HIF1A—thyroid cancer	0.00154	0.0058	CbGpPWpGaD
Cyproterone acetate—Fluid retention—Doxorubicin—thyroid cancer	0.00152	0.00206	CcSEcCtD
Cyproterone acetate—Abnormal vision—Epirubicin—thyroid cancer	0.0015	0.00205	CcSEcCtD
Cyproterone acetate—NR3C1—Generic Transcription Pathway—TRIM33—thyroid cancer	0.0015	0.00566	CbGpPWpGaD
Cyproterone acetate—Dyspnoea—Sorafenib—thyroid cancer	0.00148	0.00202	CcSEcCtD
Cyproterone acetate—AR—Nongenotropic Androgen signaling—HRAS—thyroid cancer	0.00148	0.00558	CbGpPWpGaD
Cyproterone acetate—Nausea—Vandetanib—thyroid cancer	0.00147	0.00199	CcSEcCtD
Cyproterone acetate—Dyspepsia—Sorafenib—thyroid cancer	0.00147	0.00199	CcSEcCtD
Cyproterone acetate—Coma—Doxorubicin—thyroid cancer	0.00146	0.00198	CcSEcCtD
Cyproterone acetate—Phlebitis—Epirubicin—thyroid cancer	0.00145	0.00198	CcSEcCtD
Cyproterone acetate—Rash maculo-papular—Doxorubicin—thyroid cancer	0.00145	0.00197	CcSEcCtD
Cyproterone acetate—Decreased appetite—Sorafenib—thyroid cancer	0.00145	0.00197	CcSEcCtD
Cyproterone acetate—Thrombophlebitis—Epirubicin—thyroid cancer	0.00145	0.00197	CcSEcCtD
Cyproterone acetate—Neoplasm—Doxorubicin—thyroid cancer	0.00144	0.00196	CcSEcCtD
Cyproterone acetate—Diabetes mellitus—Epirubicin—thyroid cancer	0.00144	0.00196	CcSEcCtD
Cyproterone acetate—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00144	0.00196	CcSEcCtD
Cyproterone acetate—Fatigue—Sorafenib—thyroid cancer	0.00144	0.00195	CcSEcCtD
Cyproterone acetate—AR—Generic Transcription Pathway—THRB—thyroid cancer	0.00143	0.00539	CbGpPWpGaD
Cyproterone acetate—Constipation—Sorafenib—thyroid cancer	0.00142	0.00194	CcSEcCtD
Cyproterone acetate—Eczema—Epirubicin—thyroid cancer	0.00139	0.0019	CcSEcCtD
Cyproterone acetate—Hepatic failure—Epirubicin—thyroid cancer	0.00139	0.0019	CcSEcCtD
Cyproterone acetate—Abnormal vision—Doxorubicin—thyroid cancer	0.00139	0.00189	CcSEcCtD
Cyproterone acetate—AR—Coregulation of Androgen receptor activity—CCND1—thyroid cancer	0.00137	0.00516	CbGpPWpGaD
Cyproterone acetate—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00136	0.00185	CcSEcCtD
Cyproterone acetate—NR3C1—SIDS Susceptibility Pathways—SST—thyroid cancer	0.00135	0.00509	CbGpPWpGaD
Cyproterone acetate—Phlebitis—Doxorubicin—thyroid cancer	0.00134	0.00183	CcSEcCtD
Cyproterone acetate—Hot flush—Epirubicin—thyroid cancer	0.00134	0.00182	CcSEcCtD
Cyproterone acetate—Thrombophlebitis—Doxorubicin—thyroid cancer	0.00134	0.00182	CcSEcCtD
Cyproterone acetate—Diabetes mellitus—Doxorubicin—thyroid cancer	0.00133	0.00181	CcSEcCtD
Cyproterone acetate—Menopausal symptoms—Epirubicin—thyroid cancer	0.00133	0.00181	CcSEcCtD
Cyproterone acetate—Dermatitis exfoliative—Epirubicin—thyroid cancer	0.00133	0.00181	CcSEcCtD
Cyproterone acetate—Urticaria—Sorafenib—thyroid cancer	0.00132	0.0018	CcSEcCtD
Cyproterone acetate—Abdominal pain—Sorafenib—thyroid cancer	0.00132	0.00179	CcSEcCtD
Cyproterone acetate—Body temperature increased—Sorafenib—thyroid cancer	0.00132	0.00179	CcSEcCtD
Cyproterone acetate—AR—Nongenotropic Androgen signaling—AKT1—thyroid cancer	0.00131	0.00493	CbGpPWpGaD
Cyproterone acetate—Hepatic failure—Doxorubicin—thyroid cancer	0.00129	0.00175	CcSEcCtD
Cyproterone acetate—Eczema—Doxorubicin—thyroid cancer	0.00129	0.00175	CcSEcCtD
Cyproterone acetate—Cardiac failure—Epirubicin—thyroid cancer	0.00128	0.00175	CcSEcCtD
Cyproterone acetate—Cerebrovascular accident—Epirubicin—thyroid cancer	0.00128	0.00174	CcSEcCtD
Cyproterone acetate—NR3C1—Adipogenesis—RXRA—thyroid cancer	0.00126	0.00476	CbGpPWpGaD
Cyproterone acetate—CYP19A1—FSH signaling pathway—AKT1—thyroid cancer	0.00126	0.00474	CbGpPWpGaD
Cyproterone acetate—Hot flush—Doxorubicin—thyroid cancer	0.00124	0.00168	CcSEcCtD
Cyproterone acetate—Migraine—Epirubicin—thyroid cancer	0.00123	0.00168	CcSEcCtD
Cyproterone acetate—Affect lability—Epirubicin—thyroid cancer	0.00123	0.00168	CcSEcCtD
Cyproterone acetate—Menopausal symptoms—Doxorubicin—thyroid cancer	0.00123	0.00167	CcSEcCtD
Cyproterone acetate—Dermatitis exfoliative—Doxorubicin—thyroid cancer	0.00123	0.00167	CcSEcCtD
Cyproterone acetate—Hypersensitivity—Sorafenib—thyroid cancer	0.00123	0.00167	CcSEcCtD
Cyproterone acetate—AR—Integrated Pancreatic Cancer Pathway—RXRA—thyroid cancer	0.00122	0.00461	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.00122	0.00459	CbGpPWpGaD
Cyproterone acetate—Asthenia—Sorafenib—thyroid cancer	0.00119	0.00163	CcSEcCtD
Cyproterone acetate—Cardiac failure—Doxorubicin—thyroid cancer	0.00119	0.00162	CcSEcCtD
Cyproterone acetate—Mood swings—Epirubicin—thyroid cancer	0.00119	0.00161	CcSEcCtD
Cyproterone acetate—Cerebrovascular accident—Doxorubicin—thyroid cancer	0.00118	0.00161	CcSEcCtD
Cyproterone acetate—Pruritus—Sorafenib—thyroid cancer	0.00118	0.0016	CcSEcCtD
Cyproterone acetate—Blood creatinine increased—Epirubicin—thyroid cancer	0.00117	0.0016	CcSEcCtD
Cyproterone acetate—Liver function test abnormal—Epirubicin—thyroid cancer	0.00116	0.00157	CcSEcCtD
Cyproterone acetate—CYP19A1—Biological oxidations—RXRA—thyroid cancer	0.00114	0.00432	CbGpPWpGaD
Cyproterone acetate—Migraine—Doxorubicin—thyroid cancer	0.00114	0.00155	CcSEcCtD
Cyproterone acetate—Affect lability—Doxorubicin—thyroid cancer	0.00114	0.00155	CcSEcCtD
Cyproterone acetate—Diarrhoea—Sorafenib—thyroid cancer	0.00114	0.00155	CcSEcCtD
Cyproterone acetate—Breast disorder—Epirubicin—thyroid cancer	0.00113	0.00154	CcSEcCtD
Cyproterone acetate—Aspartate aminotransferase increased—Epirubicin—thyroid cancer	0.00113	0.00153	CcSEcCtD
Cyproterone acetate—Muscular weakness—Epirubicin—thyroid cancer	0.0011	0.0015	CcSEcCtD
Cyproterone acetate—Alanine aminotransferase increased—Epirubicin—thyroid cancer	0.0011	0.0015	CcSEcCtD
Cyproterone acetate—Dizziness—Sorafenib—thyroid cancer	0.0011	0.0015	CcSEcCtD
Cyproterone acetate—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CCND1—thyroid cancer	0.0011	0.00415	CbGpPWpGaD
Cyproterone acetate—Mood swings—Doxorubicin—thyroid cancer	0.0011	0.00149	CcSEcCtD
Cyproterone acetate—Blood creatinine increased—Doxorubicin—thyroid cancer	0.00109	0.00148	CcSEcCtD
Cyproterone acetate—NR3C1—Generic Transcription Pathway—THRB—thyroid cancer	0.00108	0.00409	CbGpPWpGaD
Cyproterone acetate—Asthma—Epirubicin—thyroid cancer	0.00108	0.00147	CcSEcCtD
Cyproterone acetate—Liver function test abnormal—Doxorubicin—thyroid cancer	0.00107	0.00146	CcSEcCtD
Cyproterone acetate—AR—SIDS Susceptibility Pathways—HIF1A—thyroid cancer	0.00107	0.00403	CbGpPWpGaD
Cyproterone acetate—Pancreatitis—Epirubicin—thyroid cancer	0.00106	0.00144	CcSEcCtD
Cyproterone acetate—Vomiting—Sorafenib—thyroid cancer	0.00106	0.00144	CcSEcCtD
Cyproterone acetate—Rash—Sorafenib—thyroid cancer	0.00105	0.00143	CcSEcCtD
Cyproterone acetate—Dermatitis—Sorafenib—thyroid cancer	0.00105	0.00143	CcSEcCtD
Cyproterone acetate—Breast disorder—Doxorubicin—thyroid cancer	0.00105	0.00142	CcSEcCtD
Cyproterone acetate—Aspartate aminotransferase increased—Doxorubicin—thyroid cancer	0.00104	0.00142	CcSEcCtD
Cyproterone acetate—Headache—Sorafenib—thyroid cancer	0.00104	0.00142	CcSEcCtD
Cyproterone acetate—Muscular weakness—Doxorubicin—thyroid cancer	0.00102	0.00139	CcSEcCtD
Cyproterone acetate—Alanine aminotransferase increased—Doxorubicin—thyroid cancer	0.00102	0.00139	CcSEcCtD
Cyproterone acetate—AR—Androgen receptor signaling pathway—CCND1—thyroid cancer	0.00101	0.00381	CbGpPWpGaD
Cyproterone acetate—Asthma—Doxorubicin—thyroid cancer	0.001	0.00136	CcSEcCtD
Cyproterone acetate—Pollakiuria—Epirubicin—thyroid cancer	0.001	0.00136	CcSEcCtD
Cyproterone acetate—Nausea—Sorafenib—thyroid cancer	0.000989	0.00135	CcSEcCtD
Cyproterone acetate—Photosensitivity reaction—Epirubicin—thyroid cancer	0.000988	0.00134	CcSEcCtD
Cyproterone acetate—Weight increased—Epirubicin—thyroid cancer	0.000985	0.00134	CcSEcCtD
Cyproterone acetate—Pancreatitis—Doxorubicin—thyroid cancer	0.000982	0.00134	CcSEcCtD
Cyproterone acetate—Weight decreased—Epirubicin—thyroid cancer	0.000979	0.00133	CcSEcCtD
Cyproterone acetate—Hyperglycaemia—Epirubicin—thyroid cancer	0.000976	0.00133	CcSEcCtD
Cyproterone acetate—AR—Androgen receptor signaling pathway—PTEN—thyroid cancer	0.000975	0.00368	CbGpPWpGaD
Cyproterone acetate—AR—Gene Expression—TRIM33—thyroid cancer	0.000951	0.00359	CbGpPWpGaD
Cyproterone acetate—Renal failure—Epirubicin—thyroid cancer	0.000949	0.00129	CcSEcCtD
Cyproterone acetate—Jaundice—Epirubicin—thyroid cancer	0.000941	0.00128	CcSEcCtD
Cyproterone acetate—NR3C1—Adipogenesis—HIF1A—thyroid cancer	0.000936	0.00353	CbGpPWpGaD
Cyproterone acetate—NR3C1—AP-1 transcription factor network—CCND1—thyroid cancer	0.000929	0.00351	CbGpPWpGaD
Cyproterone acetate—Sweating—Epirubicin—thyroid cancer	0.000925	0.00126	CcSEcCtD
Cyproterone acetate—Pollakiuria—Doxorubicin—thyroid cancer	0.000925	0.00126	CcSEcCtD
Cyproterone acetate—Haematuria—Epirubicin—thyroid cancer	0.00092	0.00125	CcSEcCtD
Cyproterone acetate—Photosensitivity reaction—Doxorubicin—thyroid cancer	0.000914	0.00124	CcSEcCtD
Cyproterone acetate—Hepatobiliary disease—Epirubicin—thyroid cancer	0.000913	0.00124	CcSEcCtD
Cyproterone acetate—Weight increased—Doxorubicin—thyroid cancer	0.000911	0.00124	CcSEcCtD
Cyproterone acetate—AR—Generic Transcription Pathway—MEN1—thyroid cancer	0.000907	0.00342	CbGpPWpGaD
Cyproterone acetate—AR—Integrated Breast Cancer Pathway—BRAF—thyroid cancer	0.000907	0.00342	CbGpPWpGaD
Cyproterone acetate—Weight decreased—Doxorubicin—thyroid cancer	0.000906	0.00123	CcSEcCtD
Cyproterone acetate—Hyperglycaemia—Doxorubicin—thyroid cancer	0.000903	0.00123	CcSEcCtD
Cyproterone acetate—NR3C1—AP-1 transcription factor network—PTEN—thyroid cancer	0.000896	0.00338	CbGpPWpGaD
Cyproterone acetate—Renal failure—Doxorubicin—thyroid cancer	0.000878	0.00119	CcSEcCtD
Cyproterone acetate—Haemoglobin—Epirubicin—thyroid cancer	0.000871	0.00118	CcSEcCtD
Cyproterone acetate—Jaundice—Doxorubicin—thyroid cancer	0.00087	0.00118	CcSEcCtD
Cyproterone acetate—Haemorrhage—Epirubicin—thyroid cancer	0.000866	0.00118	CcSEcCtD
Cyproterone acetate—Hepatitis—Epirubicin—thyroid cancer	0.000866	0.00118	CcSEcCtD
Cyproterone acetate—Sweating—Doxorubicin—thyroid cancer	0.000856	0.00116	CcSEcCtD
Cyproterone acetate—Haematuria—Doxorubicin—thyroid cancer	0.000851	0.00116	CcSEcCtD
Cyproterone acetate—Connective tissue disorder—Epirubicin—thyroid cancer	0.000851	0.00116	CcSEcCtD
Cyproterone acetate—Hepatobiliary disease—Doxorubicin—thyroid cancer	0.000845	0.00115	CcSEcCtD
Cyproterone acetate—CYP19A1—Metabolism—MINPP1—thyroid cancer	0.00084	0.00317	CbGpPWpGaD
Cyproterone acetate—Visual impairment—Epirubicin—thyroid cancer	0.000835	0.00114	CcSEcCtD
Cyproterone acetate—Erythema multiforme—Epirubicin—thyroid cancer	0.000819	0.00111	CcSEcCtD
Cyproterone acetate—Eye disorder—Epirubicin—thyroid cancer	0.00081	0.0011	CcSEcCtD
Cyproterone acetate—NR3C1—SIDS Susceptibility Pathways—HIF1A—thyroid cancer	0.000809	0.00306	CbGpPWpGaD
Cyproterone acetate—Haemoglobin—Doxorubicin—thyroid cancer	0.000806	0.0011	CcSEcCtD
Cyproterone acetate—Haemorrhage—Doxorubicin—thyroid cancer	0.000802	0.00109	CcSEcCtD
Cyproterone acetate—Hepatitis—Doxorubicin—thyroid cancer	0.000802	0.00109	CcSEcCtD
Cyproterone acetate—NR3C1—Adipogenesis—PPARG—thyroid cancer	0.000796	0.00301	CbGpPWpGaD
Cyproterone acetate—Connective tissue disorder—Doxorubicin—thyroid cancer	0.000788	0.00107	CcSEcCtD
Cyproterone acetate—Angiopathy—Epirubicin—thyroid cancer	0.000786	0.00107	CcSEcCtD
Cyproterone acetate—Immune system disorder—Epirubicin—thyroid cancer	0.000783	0.00106	CcSEcCtD
Cyproterone acetate—Mediastinal disorder—Epirubicin—thyroid cancer	0.000781	0.00106	CcSEcCtD
Cyproterone acetate—CYP19A1—Integrated Breast Cancer Pathway—BRAF—thyroid cancer	0.00078	0.00295	CbGpPWpGaD
Cyproterone acetate—Chills—Epirubicin—thyroid cancer	0.000777	0.00106	CcSEcCtD
Cyproterone acetate—Visual impairment—Doxorubicin—thyroid cancer	0.000772	0.00105	CcSEcCtD
Cyproterone acetate—Alopecia—Epirubicin—thyroid cancer	0.000766	0.00104	CcSEcCtD
Cyproterone acetate—AR—Coregulation of Androgen receptor activity—AKT1—thyroid cancer	0.00076	0.00287	CbGpPWpGaD
Cyproterone acetate—Mental disorder—Epirubicin—thyroid cancer	0.000759	0.00103	CcSEcCtD
Cyproterone acetate—Erythema multiforme—Doxorubicin—thyroid cancer	0.000758	0.00103	CcSEcCtD
Cyproterone acetate—Malnutrition—Epirubicin—thyroid cancer	0.000754	0.00103	CcSEcCtD
Cyproterone acetate—Eye disorder—Doxorubicin—thyroid cancer	0.000749	0.00102	CcSEcCtD
Cyproterone acetate—NR3C1—FOXA2 and FOXA3 transcription factor networks—AKT1—thyroid cancer	0.000749	0.00283	CbGpPWpGaD
Cyproterone acetate—Tension—Epirubicin—thyroid cancer	0.00074	0.00101	CcSEcCtD
Cyproterone acetate—Angiopathy—Doxorubicin—thyroid cancer	0.000727	0.000989	CcSEcCtD
Cyproterone acetate—Immune system disorder—Doxorubicin—thyroid cancer	0.000724	0.000985	CcSEcCtD
Cyproterone acetate—Mediastinal disorder—Doxorubicin—thyroid cancer	0.000722	0.000983	CcSEcCtD
Cyproterone acetate—NR3C1—Gene Expression—TRIM33—thyroid cancer	0.000722	0.00272	CbGpPWpGaD
Cyproterone acetate—Chills—Doxorubicin—thyroid cancer	0.000719	0.000978	CcSEcCtD
Cyproterone acetate—CYP19A1—Metabolism—NDUFA13—thyroid cancer	0.000714	0.0027	CbGpPWpGaD
Cyproterone acetate—Alopecia—Doxorubicin—thyroid cancer	0.000708	0.000964	CcSEcCtD
Cyproterone acetate—Mental disorder—Doxorubicin—thyroid cancer	0.000702	0.000955	CcSEcCtD
Cyproterone acetate—Ill-defined disorder—Epirubicin—thyroid cancer	0.0007	0.000952	CcSEcCtD
Cyproterone acetate—Malnutrition—Doxorubicin—thyroid cancer	0.000698	0.000949	CcSEcCtD
Cyproterone acetate—Anaemia—Epirubicin—thyroid cancer	0.000697	0.000948	CcSEcCtD
Cyproterone acetate—Agitation—Epirubicin—thyroid cancer	0.000693	0.000943	CcSEcCtD
Cyproterone acetate—NR3C1—Generic Transcription Pathway—MEN1—thyroid cancer	0.000688	0.0026	CbGpPWpGaD
Cyproterone acetate—AR—Gene Expression—THRB—thyroid cancer	0.000688	0.0026	CbGpPWpGaD
Cyproterone acetate—Tension—Doxorubicin—thyroid cancer	0.000685	0.000931	CcSEcCtD
Cyproterone acetate—Malaise—Epirubicin—thyroid cancer	0.00068	0.000925	CcSEcCtD
Cyproterone acetate—Syncope—Epirubicin—thyroid cancer	0.000676	0.00092	CcSEcCtD
Cyproterone acetate—Leukopenia—Epirubicin—thyroid cancer	0.000675	0.000918	CcSEcCtD
Cyproterone acetate—CYP19A1—Metabolism—CHST14—thyroid cancer	0.000671	0.00253	CbGpPWpGaD
Cyproterone acetate—Loss of consciousness—Epirubicin—thyroid cancer	0.000663	0.000902	CcSEcCtD
Cyproterone acetate—AR—Integrated Breast Cancer Pathway—CCND1—thyroid cancer	0.000662	0.0025	CbGpPWpGaD
Cyproterone acetate—Cough—Epirubicin—thyroid cancer	0.000658	0.000895	CcSEcCtD
Cyproterone acetate—Ill-defined disorder—Doxorubicin—thyroid cancer	0.000647	0.000881	CcSEcCtD
Cyproterone acetate—Anaemia—Doxorubicin—thyroid cancer	0.000645	0.000877	CcSEcCtD
Cyproterone acetate—Agitation—Doxorubicin—thyroid cancer	0.000641	0.000872	CcSEcCtD
Cyproterone acetate—AR—Integrated Breast Cancer Pathway—PTEN—thyroid cancer	0.000639	0.00241	CbGpPWpGaD
Cyproterone acetate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000638	0.000867	CcSEcCtD
Cyproterone acetate—Discomfort—Epirubicin—thyroid cancer	0.000634	0.000863	CcSEcCtD
Cyproterone acetate—Malaise—Doxorubicin—thyroid cancer	0.000629	0.000856	CcSEcCtD
Cyproterone acetate—Syncope—Doxorubicin—thyroid cancer	0.000626	0.000851	CcSEcCtD
Cyproterone acetate—Leukopenia—Doxorubicin—thyroid cancer	0.000625	0.00085	CcSEcCtD
Cyproterone acetate—Oedema—Epirubicin—thyroid cancer	0.000615	0.000837	CcSEcCtD
Cyproterone acetate—Loss of consciousness—Doxorubicin—thyroid cancer	0.000613	0.000834	CcSEcCtD
Cyproterone acetate—NR3C1—AP-1 transcription factor network—TP53—thyroid cancer	0.000612	0.00231	CbGpPWpGaD
Cyproterone acetate—Cough—Doxorubicin—thyroid cancer	0.000609	0.000828	CcSEcCtD
Cyproterone acetate—AR—Generic Transcription Pathway—RXRA—thyroid cancer	0.000607	0.00229	CbGpPWpGaD
Cyproterone acetate—AR—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	0.000607	0.00229	CbGpPWpGaD
Cyproterone acetate—AR—Regulation of nuclear SMAD2/3 signaling—AKT1—thyroid cancer	0.000606	0.00229	CbGpPWpGaD
Cyproterone acetate—Shock—Epirubicin—thyroid cancer	0.000606	0.000824	CcSEcCtD
Cyproterone acetate—Nervous system disorder—Epirubicin—thyroid cancer	0.000604	0.000821	CcSEcCtD
Cyproterone acetate—Thrombocytopenia—Epirubicin—thyroid cancer	0.000603	0.00082	CcSEcCtD
Cyproterone acetate—Tachycardia—Epirubicin—thyroid cancer	0.000601	0.000817	CcSEcCtD
Cyproterone acetate—Skin disorder—Epirubicin—thyroid cancer	0.000598	0.000813	CcSEcCtD
Cyproterone acetate—Hyperhidrosis—Epirubicin—thyroid cancer	0.000595	0.000809	CcSEcCtD
Cyproterone acetate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.00059	0.000803	CcSEcCtD
Cyproterone acetate—Discomfort—Doxorubicin—thyroid cancer	0.000587	0.000798	CcSEcCtD
Cyproterone acetate—Anorexia—Epirubicin—thyroid cancer	0.000587	0.000798	CcSEcCtD
Cyproterone acetate—Hypotension—Epirubicin—thyroid cancer	0.000575	0.000782	CcSEcCtD
Cyproterone acetate—Oedema—Doxorubicin—thyroid cancer	0.00057	0.000775	CcSEcCtD
Cyproterone acetate—CYP19A1—Integrated Breast Cancer Pathway—CCND1—thyroid cancer	0.000569	0.00215	CbGpPWpGaD
Cyproterone acetate—AR—Androgen receptor signaling pathway—AKT1—thyroid cancer	0.000562	0.00212	CbGpPWpGaD
Cyproterone acetate—Shock—Doxorubicin—thyroid cancer	0.00056	0.000762	CcSEcCtD
Cyproterone acetate—Nervous system disorder—Doxorubicin—thyroid cancer	0.000558	0.00076	CcSEcCtD
Cyproterone acetate—Thrombocytopenia—Doxorubicin—thyroid cancer	0.000558	0.000759	CcSEcCtD
Cyproterone acetate—Tachycardia—Doxorubicin—thyroid cancer	0.000556	0.000756	CcSEcCtD
Cyproterone acetate—Skin disorder—Doxorubicin—thyroid cancer	0.000553	0.000752	CcSEcCtD
Cyproterone acetate—Hyperhidrosis—Doxorubicin—thyroid cancer	0.000551	0.000749	CcSEcCtD
Cyproterone acetate—CYP19A1—Integrated Breast Cancer Pathway—PTEN—thyroid cancer	0.00055	0.00207	CbGpPWpGaD
Cyproterone acetate—Dyspnoea—Epirubicin—thyroid cancer	0.000549	0.000746	CcSEcCtD
Cyproterone acetate—AR—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	0.000548	0.00207	CbGpPWpGaD
Cyproterone acetate—Anorexia—Doxorubicin—thyroid cancer	0.000543	0.000738	CcSEcCtD
Cyproterone acetate—Dyspepsia—Epirubicin—thyroid cancer	0.000542	0.000737	CcSEcCtD
Cyproterone acetate—CYP19A1—Metabolism—HPGD—thyroid cancer	0.000541	0.00204	CbGpPWpGaD
Cyproterone acetate—NR3C1—Glucocorticoid receptor regulatory network—TP53—thyroid cancer	0.000539	0.00203	CbGpPWpGaD
Cyproterone acetate—Decreased appetite—Epirubicin—thyroid cancer	0.000535	0.000728	CcSEcCtD
Cyproterone acetate—Hypotension—Doxorubicin—thyroid cancer	0.000532	0.000724	CcSEcCtD
Cyproterone acetate—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000531	0.000723	CcSEcCtD
Cyproterone acetate—Fatigue—Epirubicin—thyroid cancer	0.000531	0.000722	CcSEcCtD
Cyproterone acetate—AR—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	0.000529	0.002	CbGpPWpGaD
Cyproterone acetate—Constipation—Epirubicin—thyroid cancer	0.000526	0.000716	CcSEcCtD
Cyproterone acetate—NR3C1—Gene Expression—THRB—thyroid cancer	0.000522	0.00197	CbGpPWpGaD
Cyproterone acetate—Dyspnoea—Doxorubicin—thyroid cancer	0.000508	0.000691	CcSEcCtD
Cyproterone acetate—Feeling abnormal—Epirubicin—thyroid cancer	0.000507	0.00069	CcSEcCtD
Cyproterone acetate—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000503	0.000685	CcSEcCtD
Cyproterone acetate—Dyspepsia—Doxorubicin—thyroid cancer	0.000501	0.000682	CcSEcCtD
Cyproterone acetate—Decreased appetite—Doxorubicin—thyroid cancer	0.000495	0.000673	CcSEcCtD
Cyproterone acetate—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000492	0.000669	CcSEcCtD
Cyproterone acetate—Fatigue—Doxorubicin—thyroid cancer	0.000491	0.000668	CcSEcCtD
Cyproterone acetate—AR—Integrated Breast Cancer Pathway—KRAS—thyroid cancer	0.00049	0.00185	CbGpPWpGaD
Cyproterone acetate—Urticaria—Epirubicin—thyroid cancer	0.000489	0.000665	CcSEcCtD
Cyproterone acetate—Constipation—Doxorubicin—thyroid cancer	0.000487	0.000662	CcSEcCtD
Cyproterone acetate—Abdominal pain—Epirubicin—thyroid cancer	0.000487	0.000662	CcSEcCtD
Cyproterone acetate—Body temperature increased—Epirubicin—thyroid cancer	0.000487	0.000662	CcSEcCtD
Cyproterone acetate—Feeling abnormal—Doxorubicin—thyroid cancer	0.000469	0.000638	CcSEcCtD
Cyproterone acetate—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000466	0.000633	CcSEcCtD
Cyproterone acetate—AR—Gene Expression—TPR—thyroid cancer	0.000465	0.00175	CbGpPWpGaD
Cyproterone acetate—NR3C1—Generic Transcription Pathway—RXRA—thyroid cancer	0.00046	0.00174	CbGpPWpGaD
Cyproterone acetate—NR3C1—Regulation of nuclear SMAD2/3 signaling—AKT1—thyroid cancer	0.00046	0.00174	CbGpPWpGaD
Cyproterone acetate—NR3C1—Glucocorticoid receptor regulatory network—AKT1—thyroid cancer	0.000455	0.00172	CbGpPWpGaD
Cyproterone acetate—Hypersensitivity—Epirubicin—thyroid cancer	0.000453	0.000617	CcSEcCtD
Cyproterone acetate—Urticaria—Doxorubicin—thyroid cancer	0.000452	0.000615	CcSEcCtD
Cyproterone acetate—Body temperature increased—Doxorubicin—thyroid cancer	0.00045	0.000612	CcSEcCtD
Cyproterone acetate—Abdominal pain—Doxorubicin—thyroid cancer	0.00045	0.000612	CcSEcCtD
Cyproterone acetate—Asthenia—Epirubicin—thyroid cancer	0.000442	0.000601	CcSEcCtD
Cyproterone acetate—CYP19A1—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	0.000439	0.00166	CbGpPWpGaD
Cyproterone acetate—AR—Gene Expression—MEN1—thyroid cancer	0.000437	0.00165	CbGpPWpGaD
Cyproterone acetate—AR—Integrated Breast Cancer Pathway—TP53—thyroid cancer	0.000436	0.00165	CbGpPWpGaD
Cyproterone acetate—Pruritus—Epirubicin—thyroid cancer	0.000435	0.000592	CcSEcCtD
Cyproterone acetate—CYP19A1—Integrated Breast Cancer Pathway—KRAS—thyroid cancer	0.000422	0.00159	CbGpPWpGaD
Cyproterone acetate—Diarrhoea—Epirubicin—thyroid cancer	0.000421	0.000573	CcSEcCtD
Cyproterone acetate—Hypersensitivity—Doxorubicin—thyroid cancer	0.00042	0.000571	CcSEcCtD
Cyproterone acetate—Asthenia—Doxorubicin—thyroid cancer	0.000409	0.000556	CcSEcCtD
Cyproterone acetate—Dizziness—Epirubicin—thyroid cancer	0.000407	0.000554	CcSEcCtD
Cyproterone acetate—AR—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	0.000406	0.00153	CbGpPWpGaD
Cyproterone acetate—Pruritus—Doxorubicin—thyroid cancer	0.000403	0.000548	CcSEcCtD
Cyproterone acetate—Vomiting—Epirubicin—thyroid cancer	0.000391	0.000532	CcSEcCtD
Cyproterone acetate—Diarrhoea—Doxorubicin—thyroid cancer	0.00039	0.00053	CcSEcCtD
Cyproterone acetate—Rash—Epirubicin—thyroid cancer	0.000388	0.000528	CcSEcCtD
Cyproterone acetate—Dermatitis—Epirubicin—thyroid cancer	0.000388	0.000527	CcSEcCtD
Cyproterone acetate—Headache—Epirubicin—thyroid cancer	0.000386	0.000525	CcSEcCtD
Cyproterone acetate—AR—Generic Transcription Pathway—PPARG—thyroid cancer	0.000383	0.00145	CbGpPWpGaD
Cyproterone acetate—Dizziness—Doxorubicin—thyroid cancer	0.000377	0.000512	CcSEcCtD
Cyproterone acetate—CYP19A1—Integrated Breast Cancer Pathway—TP53—thyroid cancer	0.000375	0.00142	CbGpPWpGaD
Cyproterone acetate—AR—Integrated Breast Cancer Pathway—AKT1—thyroid cancer	0.000368	0.00139	CbGpPWpGaD
Cyproterone acetate—Nausea—Epirubicin—thyroid cancer	0.000366	0.000497	CcSEcCtD
Cyproterone acetate—Vomiting—Doxorubicin—thyroid cancer	0.000362	0.000493	CcSEcCtD
Cyproterone acetate—AR—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	0.000361	0.00136	CbGpPWpGaD
Cyproterone acetate—Rash—Doxorubicin—thyroid cancer	0.000359	0.000488	CcSEcCtD
Cyproterone acetate—Dermatitis—Doxorubicin—thyroid cancer	0.000359	0.000488	CcSEcCtD
Cyproterone acetate—Headache—Doxorubicin—thyroid cancer	0.000357	0.000485	CcSEcCtD
Cyproterone acetate—NR3C1—Gene Expression—TPR—thyroid cancer	0.000352	0.00133	CbGpPWpGaD
Cyproterone acetate—Nausea—Doxorubicin—thyroid cancer	0.000338	0.00046	CcSEcCtD
Cyproterone acetate—NR3C1—Gene Expression—MEN1—thyroid cancer	0.000331	0.00125	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Integrated Breast Cancer Pathway—AKT1—thyroid cancer	0.000317	0.0012	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism—TPR—thyroid cancer	0.000311	0.00117	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism—PRKAR1A—thyroid cancer	0.000306	0.00115	CbGpPWpGaD
Cyproterone acetate—AR—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	0.000305	0.00115	CbGpPWpGaD
Cyproterone acetate—AR—Gene Expression—RXRA—thyroid cancer	0.000292	0.0011	CbGpPWpGaD
Cyproterone acetate—NR3C1—Generic Transcription Pathway—PPARG—thyroid cancer	0.000291	0.0011	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	0.000277	0.00105	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism—SLC5A5—thyroid cancer	0.000233	0.000878	CbGpPWpGaD
Cyproterone acetate—NR3C1—Gene Expression—RXRA—thyroid cancer	0.000222	0.000837	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	0.000218	0.000823	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism—RXRA—thyroid cancer	0.000195	0.000738	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	0.00019	0.000718	CbGpPWpGaD
Cyproterone acetate—AR—Gene Expression—PPARG—thyroid cancer	0.000184	0.000696	CbGpPWpGaD
Cyproterone acetate—NR3C1—Gene Expression—PPARG—thyroid cancer	0.00014	0.000528	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism—PPARG—thyroid cancer	0.000123	0.000466	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism—PTGS2—thyroid cancer	9.71e-05	0.000367	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism—PTEN—thyroid cancer	8.47e-05	0.00032	CbGpPWpGaD
Cyproterone acetate—AR—Gene Expression—AKT1—thyroid cancer	7.29e-05	0.000275	CbGpPWpGaD
Cyproterone acetate—NR3C1—Gene Expression—AKT1—thyroid cancer	5.53e-05	0.000209	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism—AKT1—thyroid cancer	4.88e-05	0.000184	CbGpPWpGaD
